| Bioactivity | Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative[1]. |
| Name | Anditixafortide |
| CAS | 1821136-83-7 |
| Sequence | cyclo(Nal-Gly-(3-I-d-Tyr)-(N-Me-Orn(AMBA-DOTA))) |
| Formula | C60H79IN14O14 |
| Molar Mass | 1347.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nicolas Lepareur, et al. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 223, 15, 6. [2]. Ken Herrmann, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016, 57, 2. |
Anditixafortide
CAS: 1821136-83-7 F: C60H79IN14O14 W: 1347.26
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.